“The name Sentirix is derived from the Latin word sentire ‘to feel in a sensory way,"
-Dr. Erik Schwiebert, Ph.D., CEO
It is the philosophy of our team to employ human taste bud epithelial cells (hTBEC) as a platform technology on which to profile, validate and/or screen tastants so as to better understand interactions or effects on human taste pathways. We have jointly established primary and immortalized hTBEC cultures from a growing panel of individual donor-derived taste bud tissues and from tissue pooled from multiple donors. It is our collective vision that the hTBEC culture activity will be correlated closely with the taste behavior and taste genetics of the human donor or subject from which the taste bud tissue was derived and transformed into tastant screening platforms.
WHO WE ARE
Sentirix, a new CRO focused on the discovery, validation, and profiling of tastants. Sentirix was born out of collaboration between world-renowned non-profit institute Monell Chemical Senses Center and Humanized Cell Technology and Drug Discovery Company Discovery BioMed.
We aim to provide the most relevant model of human taste sensory pathways for the purpose of understanding taste profiles of compounds and taste modulators.
Monell Chemical Senses Center is a world-renowned non-profit institute focused on all aspects of the basic science of taste and smell. Monell has expertise on transforming the invention and use of primary cultures of cells derived from human taste bud tissues into higher throughput platforms for research & development related to taste.
Discovery BioMed is a boutique biotechnology company founded in 2007 on the principle that if the end goal is to discover and use drugs for human patients, it makes the most sense to integrate the most relevant human cell platforms as early as possible into the drug discovery and validation process.